Group 1 - The company, Puris (301257.SZ), announced that shareholder Guanyu Zhao Tai plans to reduce its holdings by up to 2,370,100 shares, which represents 3.00% of the company's total share capital [1]

Group 1: Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [1] - The company specializes in Site Management Organization (SMO) services to enhance the quality and efficiency of clinical trials in China [2] Group 2: Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 390.10 million and a net profit of CNY 54.16 million, with a net profit excluding non-recurring items of CNY 38.54 million [2] - The second quarter of 2025 saw a year-on-year revenue growth of 1.82% and a quarter-on-quarter growth of 21.06% [2] - The net profit for the second quarter increased by 45.17% year-on-year and 528.73% quarter-on-quarter [2] Group 3: Market Demand and Contracts - The company signed new contracts worth CNY 600 million in the first half of 2025, representing a year-on-year growth of 40.12% [2] - By the end of June 2025, the company had a backlog of contracts amounting to CNY 1.99 billion, a year-on-year increase of 9.45% [2] Group 4: Project Execution and Quality Control - The company has managed over 4,000 SMO projects, with 2,428 currently active [2] - Quality control is emphasized through the establishment of over 280 standard operating procedures and continuous training for employees [5] Group 5: Industry Trends and Opportunities - The Chinese innovative drug industry is entering a new phase of high-quality development, driven by policy support and active overseas business development (BD) transactions [2] - In the first half of 2025, the number of BD transactions in China's innovative drug sector reached 72, with a total transaction value of USD 60 billion [3]

Group 1 - On September 12, two listed companies had their restricted shares unlocked, with a total market value of approximately 5.33 million yuan [1] - The specific details of the restricted share unlock are as follows: - Company "好想你" (stock code: 002582) had 110,000 shares released from equity incentive restrictions [1] - Company "普蕊斯" (stock code: 301257) had 92,500 shares released from equity incentive restrictions [1]

Core Insights - On August 29, 2023, Prasis saw a stock price increase of 20.01% with a trading volume of 278 million yuan [1] - As of August 29, 2023, Prasis had a total margin trading balance of 62.69 million yuan, which is 1.82% of its market capitalization, indicating a low financing balance compared to the past year [1] - For the first half of 2025, Prasis reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2] Financing and Margin Trading - On August 29, 2023, Prasis had a financing buy amount of 18.66 million yuan and a financing repayment of 20.31 million yuan, resulting in a net financing buy of -1.65 million yuan [1] - The margin trading data indicates that Prasis had no short selling activity on August 29, 2023, with a short selling balance of 0.00 yuan, which is at a high level compared to the past year [1] Shareholder and Institutional Holdings - As of July 31, 2023, Prasis had 8,735 shareholders, a decrease of 7.55% from the previous period, while the average number of circulating shares per shareholder increased by 8.16% to 8,622 shares [2] - As of June 30, 2025, among the top ten circulating shareholders, Tianhong Medical Health A held 1.43 million shares, a decrease of 17,600 shares from the previous period, while Rongtong Health Industry Flexible Allocation Mixed A/B increased its holdings by 100,000 shares to 1 million shares [3]

Group 1 - The company, Pruis, announced on the evening of September 9 that its third supervisory board's fifteenth meeting approved the proposal for revising and handling business change registration and filing [2]

Group 1 - The company announced the approval of multiple proposals during the 15th meeting of the third board of directors, including the re-election of non-independent directors [2]

Group 1 - The core point of the article is that the board of directors of the company has agreed to nominate Mr. Ma Yuping as a candidate for the non-independent director of the third board of directors [2]

普蕊斯（上海）医药科技开发股份有限公司 重大投资决策管理制度 普蕊斯（上海）医药科技开发股份有限公司 重大投资决策管理制度 第一章 总 则 第一条 为加强普蕊斯（上海）医药科技开发股份有限公司（以下简称"公 司"）重大投资决策管理水平，规范公司的重大投资行为，防范投资风险，保证 投资的安全，提高投资的效益，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《普蕊斯（上海）医药科技开发股份有限公司章程》（以下简称"《公司 章程》"）的有关规定，制定本制度。 第二条 本制度所称投资包括固定资产投资、金融资产投资和长期股权投资。 金融资产投资包括： （一）对子公司投资； （二）对合营公司投资； （三）对联营公司投资； （四）对被投资企业不具有共同控制或重大影响，并且在活跃市场中没有报 价、公允价值不能可靠计量的权益性投资。 第三条 本制度适用于公司及所属控股企业（以下简称所属企业）所有投资 业务。公司实行股东会、董事会、总经理分层决策制度，下属分公司无权决策对 外投资，子公司在公司授权范围内进行投资决策。 第四条 公司投资必须符合公司的发展战略，坚持成本效益原则，达到合理 投资收益标准，做到为公司全体股东谋求 ...

普蕊斯 防范控股股东、实际控制人及其他关联方占用公司资金管理制度 普蕊斯（上海）医药科技开发股份有限公司防范 控股股东、实际控制人及其他关联方占用公司资金管理制度 第一章 总则 第一条 为了加强和规范普蕊斯（上海）医药科技开发股份有限公司（以下 简称"公司"）的资金管理，建立防范控股股东、实际控制人及其他关联方占用公 司资金行为的长效机制，杜绝控股股东、实际控制人及其他关联方占用公司资金 行为的发生，有效保护公司、股东及其他利益相关人的合法权益，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司监管指引第 8 号——上 市公司资金往来、对外担保的监管要求》《深圳证券交易所创业板股票上市规则》 等有关法律、法规、规范性文件以及《普蕊斯（上海）医药科技开发股份有限公 司章程》（以下简称"《公司章程》"）的相关规定，特制定本制度。 第二条 公司及纳入公司合并会计报表范围的子公司与控股股东、实际控 制人、其直接或间接控制的其他企业（公司及公司合并报表范围的子公司除外） 及其他关联方之间资金往来适用本制度。 除本条规定外，本制度所称的公司均指公司及纳入公司合并会计报表范围的 子公司。本制度所称的控股股 ...

第一条 为了进一步加强普蕊斯（上海）医药科技开发股份有限公司（以下 简称"公司"）与投资者和潜在投资者（以下统称"投资者"）之间的信息沟通， 促进公司与投资者之间建立长期、稳定的良性关系，提升公司的投资价值与诚信 形象，切实保护投资者的合法权益，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司投资者关系管理工作指引》《深圳证券交易所创业板股 票上市规则》（以下简称"《上市规则》"）《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》（以下简称"《规范运作指引》"）等有关 法律、法规及《普蕊斯（上海）医药科技开发股份有限公司章程》（以下简称"《公 司章程》"）的规定，结合本公司实际情况，特制定本制度。 第二条 投资者关系管理是指上市公司通过便利股东权利行使、信息披露、 互动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资 者对上市公司的了解和认同，以提升上市公司治理水平和企业整体价值，实现尊 重投资者、回报投资者、保护投资者目的的相关活动。 第三条 公司开展投资者关系管理活动，应当以已公开披露信息作为交流内 容，不得以任何方式透露或者泄露未公开披露的重大 ...